Your browser is no longer supported. Please, upgrade your browser.
Settings
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-5.63 Insider Own0.10% Shs Outstand393.75M Perf Week1.59%
Market Cap99.60B Forward P/E14.61 EPS next Y17.31 Insider Trans- Shs Float393.75M Perf Month9.72%
Income-2446.20M PEG- EPS next Q3.32 Inst Own89.80% Short Float1.47% Perf Quarter16.80%
Sales16.30B P/S6.11 EPS this Y23.00% Inst Trans-0.05% Short Ratio1.60 Perf Half Y-11.07%
Book/sh183.69 P/B1.38 EPS next Y22.45% ROA- Target Price293.06 Perf Year-23.09%
Cash/sh5.77 P/C43.80 EPS next 5Y9.70% ROE- 52W Range195.50 - 340.34 Perf YTD-19.06%
Dividend- P/FCF- EPS past 5Y-50.40% ROI-1.30% 52W High-25.68% Beta0.68
Dividend %- Quick Ratio0.90 Sales past 5Y33.40% Gross Margin71.80% 52W Low29.39% ATR5.40
Employees31200 Current Ratio1.00 Sales Q/Q48.10% Oper. Margin- RSI (14)60.71 Volatility2.36% 1.93%
OptionableYes Debt/Eq0.59 EPS Q/Q86.30% Profit Margin- Rel Volume0.63 Prev Close255.56
ShortableYes LT Debt/Eq0.53 EarningsAug 08 BMO Payout- Avg Volume3.63M Price252.95
Recom1.90 SMA203.97% SMA505.94% SMA200-5.78% Volume2,280,129 Change-1.02%
Jul-27-16Reiterated Leerink Partners Outperform $272 → $294
Jul-25-16Initiated Credit Suisse Outperform $327
May-13-16Reiterated Mizuho Neutral $250 → $232
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
Apr-07-16Resumed JP Morgan Overweight
Apr-07-16Reiterated UBS Buy $366 → $300
Apr-07-16Downgrade Susquehanna Positive → Neutral
Apr-06-16Downgrade Mizuho Buy → Neutral $330 → $250
Mar-31-16Reiterated Canaccord Genuity Buy $340 → $320
Feb-23-16Reiterated Mizuho Buy $354 → $330
Feb-23-16Reiterated Deutsche Bank Buy $308 → $339
Feb-19-16Initiated Wells Fargo Outperform
Nov-24-15Reiterated Mizuho Buy $340 → $354
Nov-13-15Reiterated Mizuho Buy $337 → $340
Oct-28-15Reiterated Leerink Partners Outperform $311 → $342
Oct-09-15Initiated Mizuho Buy
Sep-29-15Initiated Nomura Buy
Jul-29-16 05:52PM  The Lowdown On Activist Investing
Jul-28-16 12:00PM  Allergan (AGN) Stock Is Thursdays Chart of the Day
10:47AM  Billionaire Dan Loeb Reiterates Bullish Thesis on Baxter, Holds on to Allergan Stake & Other Market Commentaries at Insider Monkey
09:09AM  Teva Pharmaceutical Finance Issued the Most High-Grade Bonds
08:42AM  Teva Said Close to Closing $40.5 Billion Allergan Deal
Jul-27-16 05:41PM  Teva, Allergan win U.S. antitrust approval for generics deal Reuters
04:31PM  Teva expect to close $40.5B Allergan generic deal next week
03:43PM  [$$] Teva, Allergan Get FTC Approval for Generics Purchase at The Wall Street Journal
03:35PM  FTC approves Teva's $40.5B deal for Allergan's generics business at bizjournals.com
03:14PM  ALLERGAN PLC Files SEC form 8-K, Other Events
02:42PM  Teva purchase of Allergan generics business approved with conditions Reuters
Jul-26-16 05:39PM  Third Point's 1st-half returns boosted by energy credit investments Reuters
12:52PM  Jerome Dodson Comments on Allergan
12:41PM  Jerome Dodson's Parnassus Fund 2nd Quarter Commentary
Jul-25-16 02:30PM  Street Talk: Mondelez & more
01:13PM  Allergan Gets Positive Opinion For Its Truberzi For Irritable Bowel Syndrome With Diarrhoea Treatment In Adults
01:08PM  Credit Suisse says Allergan's drug pipeline is 'underappreciated' at CNBC
11:30AM  Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults PR Newswire
10:54AM  Jim Cramer -- I Agree With the Analysts on Gap, Allergan
10:36AM  Why Traders Are Watching Tesla, SolarCity, Allergan & Other Stocks Today at Insider Monkey
10:34AM  Specialty Pharma: Earnings Better Be Goodor Else at Barrons.com
08:11AM  Analysts' Actions -- Allergan, Alaska Air, Tableau, PulteGroup and More
06:40AM  Coverage initiated on Allergan by Credit Suisse
Jul-22-16 10:31AM  Investors scrap for Teva Pharmaceutical bonds Reuters
Jul-21-16 12:07PM  Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin at The Wall Street Journal
11:25AM  Amgen (AMGN) Stock Rises on 'Non-Inferior' Late-Stage Trial Results
10:39AM  Valeant & Endo: Imagining a World With No Drug Pricing Controversies at Barrons.com
10:16AM  Amgen, Allergan biosimilar found as effective as Roche cancer drug Reuters
09:00AM  Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer PR Newswire
Jul-20-16 05:36PM  [$$] Jury Acquits Former Johnson & Johnson Unit Execs of Felony Fraud at The Wall Street Journal
03:31PM  Weitz Funds Comments on Allergan
01:56PM  Weitz Funds' 2nd Quarter 2016 Value Fund Commentary
01:56PM  Wally Weitz's Partners Value Fund 2Q 2016 Quarterly Commentary
07:59AM  Actress Marisa Tomei Partners with Allergan to Raise Awareness of Chronic Dry Eye PR Newswire
Jul-19-16 07:59AM  Allergan and Adamas Announce New Expanded Indication for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease PR Newswire
07:54AM  'Incredible' Demand for Teva's $15B Bond Deal Pushes Yields Lower at Barrons.com
02:19AM  Teva Pharm prices $15 bln in notes to fund Allergan generics deal Reuters
Jul-18-16 04:56PM  Edwards Lifesciences (EW) Q2 Earnings: Will It Be a Miss?
01:57PM  Allergan Files De Novo Application For Approval Of Oculeve Intranasal Tear Neurostimulator
01:21PM  [$$] Teva Finalizes Bond Sale at The Wall Street Journal
12:58PM  Outperform With A Crowded Positions Strategy
12:11PM  Teva ratchets in pricing on new benchmark bond Reuters
08:17AM  URGENT-Teva to sell up to seven-tranche US dollar bond Monday Reuters
08:05AM  Allergan Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator PR Newswire
Jul-15-16 03:13PM  Pfizer's Split: A Double-Edged Sword? at Forbes
02:10PM  Top 7 Research Reports for July 15, 2016
09:23AM  Teva Makes Good Use of Rate Climate to Fund Allergan deal
Jul-14-16 12:53PM  Turns out nobody ever really wanted Bill Ackman at Valeant
12:20PM  Why Tevas $20 Billion Bond Sale Makes Sense, as Long as Its a Fixed Rate at 24/7 Wall St.
08:10AM  Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
01:18AM  Teva Surges on Robust Outlook, Allergan Deal at Bloomberg
Jul-13-16 07:28PM  Teva Pharmaceuticals shares up after it raises second-quarter estimates at CNBC
06:27PM  Ruane Cunniff Comments on Allergan
04:36PM  Teva Forecasts Growth After Expected Actavis Deal Closes
01:37PM  Welcome to the Hard Part, Teva at Bloomberg
01:02PM  US STOCKS-Wall St record-setting rally peters out
11:35AM  Teva says Allergan deal to close 'any time', expects U.S. antitrust clearance Reuters
11:04AM  How Will Recent Developments Affect Allergan?
10:55AM  Why the Teva Acquisition Proves It Is a Stock to Own for the Decade at 24/7 Wall St.
10:36AM  Why Traders Are Talking About Allergan, Teva, and 3 Other Stocks Today at Insider Monkey
10:13AM  Teva says Allergan deal to close 'any time' Reuters
09:51AM  Sequoia Fund Drops Valeant, Allergan and Cabela's
09:39AM  Allergan extends Teva deal deadline Reuters
09:27AM  Stocks to Watch: Diamondback Energy, Imprivata, American Airlines, Juno Therapeutics at The Wall Street Journal
09:25AM  [$$] Teva, Allergan Tweak Acquisition Agreement at The Wall Street Journal
09:04AM  How Does Allergans Financial Guidance Look for 2016?
07:47AM  Teva Raises Q2 Guidance; to Unveil 2016-2019 View
06:52AM  ALLERGAN PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Jul-12-16 08:05PM  How Did Allergans Anda Distribution Segment Perform?
06:34PM  [$$] Teva Raises Guidance at The Wall Street Journal
05:11PM  Teva Lifts Q2 Guidance Ahead Of Post-Buyout Long-Term Forecast
04:04PM  Shire Stock Up As Eye Drug Wins Early Approval, Broad Label
01:24PM  Allergan Still Has More to Prove
09:34AM  [$$] Shire boosted by FDA approval of dry eye drug at Financial Times
09:07AM  How Did Allergans International Brands Segment Perform?
07:30AM  Allergan to Host Second Quarter 2016 Earnings Conference Call and Webcast PR Newswire
Jul-11-16 10:06PM  How Did Allergans US Medical Aesthetics Segment Perform?
09:34PM  FDA approves Shire's keenly-watched eye drug Reuters
09:06AM  How Did Allergans US Brands Segment Perform?
Jul-08-16 12:05PM  Pfizers Recent Corporate and Pipeline Developments
11:37AM  The Hypocrisy That's Turned Hedge Fund Activists Into Billionaires at Forbes
11:07AM  How Has Allergans Revenue Stream Changed in Recent Quarters?
10:47AM  How Will AstraZeneca (AZN) Stock Be Affected by Generic Copies?
09:07AM  Why Allergan Acquired Topokine Therapeutics?
06:33AM  Goldman Sachs Calls These Stocks Buys, but the Charts Disagree
Jul-07-16 08:05AM  Allergan Demonstrates a Strong Commitment to America's First Responders Donating Over $1 Million Worth of REFRESH® Eye Drops PR Newswire
Jul-06-16 06:43PM  Cramer: My biggest mistakes made investing at CNBC
12:07PM  Analyst Estimates for Pfizer: Why Should We Take Notice?
09:39AM  AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Jul-05-16 02:06PM  How Did Hedge Funds Favourite Healthcare Stocks Perform during Q2? at Insider Monkey
07:00AM  Juniper Pharmaceuticals Announces that Merck KGaA, Darmstadt, Germany, has Obtained Regulatory Approval for OneCrinone® in Japan PR Newswire
Jul-04-16 11:06AM  Insights into Pfizers Profitability and Financial Guidance
Jul-02-16 09:04AM  3 Issues That Every Healthcare Investor Should Consider at Motley Fool
08:05AM  3 Large-Cap Stocks to Buy in July at Motley Fool
12:01AM  [$$] Biotech Bargain at Barrons.com
Jul-01-16 03:52PM  Why a Hedge Fund Heavyweight Is Blasting Donald Trump on Trade
09:54AM  Biogen: Not Worth A Buy Unless It Buys
07:43AM  Allergan's 'double-chin' treatment gets positive opinion in Sweden at MarketWatch
07:30AM  Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Patients With Submental Fullness PR Newswire
04:42AM  New Global Research from Allergan Shows New Attitude to Beauty as Women Seek Confidence Over Youth PR Newswire
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians' offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.